Three high-quality diverse stocks set for long-term growth
Professional investor James Spence of the TM Cerno Global Leaders fund picks three quite different businesses that he thinks will grow next year as we emerge from the pandemic.
The TM Cerno Global Leaders fund invests in a diverse array of global businesses that the managers believe will occupy leadership positions in their sectors for the next ten years or more.
The portfolio has very little overlap with other quality equity strategies. Below is a selection of three quite different businesses that we believe are poised for growth as we emerge from the pandemic next year.
Nervous systems for cars
Despite many articles suggesting that there is a growing reluctance to own motor vehicles (particularly among the younger generation), the car is not dead. Aptiv (NYSE: APTV) focuses on revolutionising the architecture of vehicles.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Architecture in this context is conceived as the “brain and nervous system” required to enable autonomous driving. The electrical power consumption of cars has risen sixtyfold since 1995, while signal distribution speeds (in essence, how rapidly power and data move through the vehicle) have risen by a factor of 20. Yet today’s vehicle data, signal and power distribution systems rely on decades-old technology.
Self-driving vehicles of the future need to have the networking capability to move vast amounts of data from the vehicle’s “eyes and ears” (sensors) to the “brain” (computing platform) for analysis and decision making. Aptiv has expertise in both key domains, from connectors and distribution systems to advanced software for passenger safety. The company is the leading provider of such “nervous systems” with a 25% share of the overall market.
PPG Industries (NYSE: PPG) is one of the world’s largest coatings companies and the only truly global supplier. Its diversified product portfolio touches a broad swathe of the economy, from specialised, high-performance industrial applications, to consumer architectural paints.
Much of the portfolio involves selling to business customers, which means that quality, consistency and timeliness of service are critical. This in turn limits the potential for disruption from budding competitors.
As the world shifts from internal combustion engines to electric vehicles, the coatings developed by PPG will be integral to the proper functioning of battery packs, boosting the value of PPG’s content per vehicle by two to four times. PPG’s return on capital is more than twice that of its European peer, AkzoNobel.
Profit from a return to the pub
The pandemic has caused significant headwinds for Heineken’s (Amsterdam: HEIA) business, which revolves around social drinking.
Earnings forecasts have been revised down by more than 50% since the start of the year, reflecting this lower demand. However, while some consumer behaviours have been altered by the pandemic, human beings are creatures of habit – we will all return to pubs and bars in time.
Despite its near-term travails, the company operates in a consolidated market, which is enjoying ever-increasing demand. Heineken’s scale in distribution is a key advantage, particularly in emerging markets, and its brand has by far the greatest global reach. While beer is an industry characterised by a vibrant start-up scene, most brands migrate towards one of the big brewers once a certain scale is reached.
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
James Spence is managing partner at Cerno Capital.
-
Barclays begins paying up to £100 compensation to customers after banking outage
Barclays will pay up to £7.5 million in compensation to customers after its banking services were disrupted by an IT outage
By Daniel Hilton Published
-
Review: Shangri-La Paris – an ode to the world’s best food
Natasha Langan enjoys fine French and Chinese cuisine at the Shangri-La Paris
By Natasha Langan Published
-
The star small and mid-cap stocks income investors have overlooked
Opinion Thomas Moore, senior investment director, Aberdeen, highlights three company stocks as he shares where he would put his money
By Thomas Moore Published
-
Falling revenues and mounting debt spell trouble for Jumia Technologies
Struggling African e-commerce platform Jumia Technologies looks headed for the exit, says Dr Matthew Partridge.
By Dr Matthew Partridge Published
-
Chemring Group: an explosive investment opportunity in defence
European states are raising their military spending, and Chemring Group looks well placed to profit
By Rupert Hargreaves Published
-
Next reports £1 billion in annual profits for the first time – what's next for the retailer?
Clothing retailer Next has become only the fourth member of its sector to surpass £1 billion in annual profits. What does this mean for the company's future?
By Dr Matthew Partridge Published
-
Best of British bargains: cash in on undervalued companies in the UK stock market
Opinion Michael Field, Chief Equity Market Strategist, EMEA, Morningstar, selects three attractive UK stocks where he'd put his money
By Michael Field Published
-
Building firm Keller presents low debt and ample scope for growth
Geotechnical contractor Keller, which supports vital global infrastructure, boasts rising profits and a cheap valuation
By Dr Mike Tubbs Published
-
PZ Cussons share price down 75% in last decade – why it's one to watch
Opinion Once-strong consumer-goods business PZ Cussons is out of favour with the market. That spells opportunity for investors, says Jamie Ward
By Jamie Ward Published
-
Cash in on the biotech sector with specialist trust BioPharma
Opinion BioPharma has an attractive niche in lending to asset-rich biotechnology companies
By Rupert Hargreaves Published